Novo Nordisk Secures FDA Approval for Awiqli®, First Once-Weekly Basal Insulin for Type 2 Diabetes
NVO is trading near its 52-week low of $35.85 (2.0% above the low).
Summary
Novo Nordisk announced FDA approval for Awiqli® (insulin icodec-abae), the first and only once-weekly basal insulin for adults with type 2 diabetes, with a US launch anticipated in the second half of 2026.
Key Events · Product Development and Regulatory · NVO
-
FDA Approval for Awiqli®
The US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL for adults with type 2 diabetes.
-
First Once-Weekly Basal Insulin
Awiqli® is the first and only once-weekly, long-acting basal insulin approved by the FDA, offering a significant convenience advantage over daily injections.
-
US Launch Expected H2 2026
Novo Nordisk anticipates launching Awiqli® nationwide in the US in the second half of 2026.
-
Strong Clinical Efficacy
The approval is supported by the ONWARDS phase 3a program, which demonstrated efficacy in HbA1c reduction consistent with the daily basal insulin class, with a similar safety profile.
Analysis · NVO · Life Sciences
This FDA approval for Awiqli® marks a significant milestone for Novo Nordisk, introducing the first and only once-weekly basal insulin for adults with type 2 diabetes. This innovation could substantially improve patient adherence and quality of life by reducing daily injections to a single weekly dose, potentially capturing significant market share in the competitive diabetes treatment landscape. The approval strengthens Novo Nordisk's leading position in diabetes care and provides a strong positive catalyst, especially as the stock is currently trading near its 52-week low. The planned US launch in the second half of 2026 positions the company for future revenue growth.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVO was trading at $36.58 on NYSE in the Life Sciences sector, with a market capitalization of approximately $163.2B. The 52-week trading range was $35.85 to $81.44. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.